Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 7 for:    enbrel | Recruiting, Not yet recruiting Studies | Ankylosing Spondylitis

Faecal Analyses in Spondyloarthritis Therapy (FAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03839862
Recruitment Status : Recruiting
First Posted : February 15, 2019
Last Update Posted : March 20, 2020
Sponsor:
Information provided by (Responsible Party):
Region Skane

Brief Summary:

This study evaluates the intestinal microbiome and disease activity in patients with spondyloarthropathies receiving immunosuppressive therapy.

Patients will be analysed at two time points in reference to two predefined primary endpoints:

  • Changes in intestinal microbiome
  • Response to therapy

The investigators want to evaluate if successful treatment of spondylarthropathy coincide with specific changes in the gut flora.


Condition or disease Intervention/treatment
Spondyloarthropathies Ankylosing Spondylitis Drug: TNF-inhibition

Detailed Description:

Tumor necrosis factor (TNF)-inhibition is an efficient medication for the treatment of spondyloarthropathy. In a substantial number of cases however, these medications remain ineffective. At present, the scientific community has limited understanding of why some patients are resistant to this medication. The purpose of this study is to understand if the gut flora may associate with treatment response.

Spondyloarthropathies are associated with inflammatory bowel diseases in terms of epidemiology and molecular pathogenesis. Recent studies have also associated spondyloarthropathies with intestinal dysbiosis.

This study is of observational character and integrated in the routine clinical care of patients with spondyloarthropathies at the Rheumatology Clinic, Skane University Hospital, Lund, Sweden. Study participants are asked to deliver blood and fecal sampling at two time-points together with clinical evaluation of disease activity. With an estimated inclusion of 50 patients, at least 20 responders and 20 non-responders are expected to be included and to be compared to each other.

Our primary goal is to investigate the association between change in intestinal microbiome and clinical response to therapy.

In our secondary analyses we will investigate if intestinal microbiome and intestinal inflammation at baseline may predict response to, and adherence to, therapy in these patients.

If successful treatment response of spondyloarthropathy is associated with specific alterations of the gut flora, these results may guide future studies on the impact of dysbiosis and probiotics on this disease.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Faecal Analyses in Spondyloarthritis Therapy: A Prospective Observational Study of the Intestinal Microbiome in Patients With Spondyloarthropathy Receiving TNF-inhibition.
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Group/Cohort Intervention/treatment
Responder
Patient responding to TNF-inhibition
Drug: TNF-inhibition
Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab

non-Responder
Patient not responding to TNF-inhibition
Drug: TNF-inhibition
Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab




Primary Outcome Measures :
  1. Change in gut flora [ Time Frame: Change from baseline Dysbiosis Index Score at 6 months ]
    Change in Dysbiosis Index Score att follow up compared to baseline. The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis.

  2. Change in disease activity/treatment response at follow up [ Time Frame: Change from baseline BASDAI at 6 months ]
    Change in Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), an established index of disease activity in spondylarthropathies between 0-10, where 10 equals maximum activity


Secondary Outcome Measures :
  1. Intestinal gut flora in spondyloarthropathies [ Time Frame: Analysis made at study start /baseline ]
    Intestinal gut flora based on DNA-based microbial analysis of fecal samples (Dysbiosis Index Score). The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis.

  2. Intestinal gut inflammation [ Time Frame: Analysis made at study start /baseline ]
    Assessment of intestinal inflammation by measurement of faecal calprotectin, an established biomarker of intestinal inflammation

  3. Adherence to immunosuppressive therapy [ Time Frame: Analysis made at 6 months follow up ]
    Is the patient still prescribed the same immunosuppressant compared to baseline?


Biospecimen Retention:   Samples Without DNA
Blood and faecal sampling


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This study encompasses consecutive patients with spondyloarthropathy who by their physician at the Rheumatology Clinic, Skåne University Hospital, have been prescribed a TNF-inhibitor.

Patients who are willing to comply with the study protocoll are included. The study population is consequently not a sample, but encompasses a majority of spondyloarthropathy patients being prescribed this medication at our University clinic.

Criteria

Inclusion Criteria:

  • Fulfilling the Assessment of SpondyloArthritis International Society classification criteria for spondyloarthropathy.
  • About to commence treatment with TNF-inhibition

Exclusion Criteria:

  • Failure to understand protocol
  • A history of alcohol abuse
  • Any history of diverticulitis
  • A history of failure to comply with prescribed medication
  • Ongoing biological therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03839862


Contacts
Layout table for location contacts
Contact: Kristofer Andréasson, MD PhD +4646172153 kristofer.andreasson@med.lu.se
Contact: Johan Karlsson Wallman, MD PhD +4646172140 johan.81.karlsson@gmail.com

Locations
Layout table for location information
Sweden
Reumatologi SUS Lund, Region Skåne Recruiting
Lund, Sweden, 221 85
Contact: Kristofer Andréasson, MD PhD    +4646171000    kristofer.andreasson@med.lu.se   
Contact: Johan Karlsson Wallman, MD PhD    +4646171000    johan.81.karlsson@gmail.com   
Sponsors and Collaborators
Region Skane
Investigators
Layout table for investigator information
Principal Investigator: Kristofer Andréasson, MD PhD Lund University Hospital
Layout table for additonal information
Responsible Party: Region Skane
ClinicalTrials.gov Identifier: NCT03839862    
Other Study ID Numbers: FAST1
First Posted: February 15, 2019    Key Record Dates
Last Update Posted: March 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Spondylarthritis
Spondylarthropathies
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Ankylosis
Joint Diseases
Arthritis